key: cord-0573376-k8802pwq
authors: Deng, Xiaobing; Yu, Xiaoyu; Pei, Jianfeng
title: Regulation of interferon production as a potential strategy for COVID-19 treatment
date: 2020-03-02
journal: nan
DOI: nan
sha: 52bf4421c628d0a0c4bc116732025facd0a4c186
doc_id: 573376
cord_uid: k8802pwq

Regulating the upstream of the cytokines production could be a promising strategy to the treatment of COVID-19. We suggest to pay more attention to the dysregulated IFN-I production in COVID-19 and to considerate cGAS, ALK and STING as potential therapeutic targets preventing cytokine storm. Approved drugs like suramin and ALK inhibitors are worthy of clinical trials.

associated molecular patterns (DAMPs) by cGAS, like self-DNA released by apoptotic cells, also arises human inflammatory disease (5) . And STING gain-of-function mutants is responsible for various devastating autoimmune diseases known as STING-associated vasculopathy with onset in infancy (SAVI) (6) (7) (8) . Excessive inflammation induced by STING disorder damages the body's own cells and tissues, causing SAVI phenotype including systemic inflammation, destructive skin lesions, and interstitial lung disease (6) . In SARS infected mice model, rapid spreading virus ultimately induced a delayed IFN-I production and promoted severe disease in the late state by boosting accumulation of pathogenic monocyte-macrophages, resulting in lung immunopathology, vascular leakage, and suboptimal T cell responses(9). In SARS patients, high IFN and IFNstimulated chemokine levels, plus robust antiviral IFN-stimulated gene expression, accompanied early SARS sequelae and poor clinical course (10). In Sepsis, a life-threatening organ dysfunction caused by infection, and silica-induced lung inflammation, STING dependent disordered IFN-I response was also reported (11, 12) . In COVID-19, the lung damage level and the level of cytokines in both ICU patients and non-ICU patients were higher than those in healthy adults (2) . Similar phenomena were also found in SARS patients and silica-induced lung inflammation patients. Given that preventing cGAS-STING pathway from aberrant activation may be a suitable strategy for treatment of severe lung diseases induced by SARS-CoV, SARS-CoV-2 or other pathogens, we suppose that several proteins in the pathway are potential targets for COVID-19 ( Figure 1 ). STING is a popular drug target as immunosuppressants in recent years (14, 15) . Several STING regulatory molecules were developed by academy and industry (16) . Unfortunately, none STING directly-target molecules has been marketed yet.

To obtain potential STING safety inhibitors, we screened the FDA-approved drug library using virtual screening. We selected 6 compounds through the screening. The molecular structures of these 6 compounds are shown in Figure 2 . The selected compounds were evaluated with two cell-based assays. Sorafenib potently inhibits vaccinia virus induced IFN- production in THP1 cells ( Fig 3A) . And in Hela cells, sorafenib inhibited dsDNA induced IRF3 phosphorylation dose dependent after incubating for 12 hours or 20 hours ( Fig 3B) . These data indicated that, sorafenib is a potent inhibitor of STING pathway.

Further direct STING-Sorafenib binding assays might give more evidence. Figure 3 . Sorafenib is shown to be a potent STING inhibitor Using drugs targeting STING regulatory proteins to regulate IFN-I production is also a potential strategy to meet an urgent need for marketed drugs. Recently, anaplastic lymphoma kinase (ALK) inhibitors were reported to be a specific and effective STING antagonists both in vitro and in vivo (17) . ALK directly interacts with epidermal growth factor receptor (EGFR) to trigger serinethreonine protein kinase AKT phosphorylation and activates interferon regulatory factor 3 (IRF3) and nuclear factor B (NF-B) signaling pathways, enabling STING-dependent rigorous inflammatory responses (12) . Thus, ALK-targeted drugs have great potential in treating moderate to severe lung inflammation in COVID- 19. cGAS, which is the cytosolic DNA sensor upstream STING, is also a potential therapeutic target for IFN-I regulating. Suramin, an approved antiparasitic drug, was reported to be an effective cGAS antagonist by displacing the bound DNA from cGAS (18) . Suramin was reported as an entry inhibitor for various of viruses including DNA virus and RNA virus (19) (20) (21) (22) (23) . Clinical trial application of Suramin had been submitted in China on 21th Feb(24).

Cytokines directed antagonists, such as Adalimumab (TNF-) and CMAB806 (IL-6) have been applied in clinical trials against COVID-19(24). Diverse cytokines are involved in the pathology of COVID-19. Thus, regulating the upstream of the cytokines production could be a promising strategy.

Collectively, we suggest to pay more attention to the dysregulated IFN-I production in COVID-19 and to considerate cGAS, ALK and STING as potential therapeutic targets preventing cytokine storm. Approved drugs like suramin and ALK inhibitors are worthy of clinical trials.

Virtual Screening. The c-di-GMP bond to STING crystal complex was used as receptor (PDB code:4EMT). And the commercial FDA-approved drug data containing 2684 compounds was downloaded from Selleck website. A two-step molecular docking scheme was performed, which has been successfully used in discovering active molecules in other systems(25). Virtual screening using FDA-approved drugs against cGAS and ALK were also performed but no potential compounds other than known inhibitors were found. The general procedure was as following: all compounds were docked into the ligand binding pockets with the rigid-body docking approach of the DOCK 6.1(26) program using the default parameters. Two hundred compounds with the lowest The compound formed at least two hydrogen bonds. (2) The compound was not a polypeptide.

Type I-IFN bioassay. Type I-IFN concentration was measured as previously described (27) . THP1 cells were starved by 2% FBS containing DMEM for 48 h before infected with vaccinia virus.

reporter cells were planted to 96-well plates and incubated with human cell culture supernatants.

Recombinant human IFN-β (R&D Systems) was used as standards. 4 h later, cells were lysed and measured by Luciferase Reporter Assay System (Promega).

Western blot. HeLa cells planted on 10-cm dishes (1×107 cells/dish) were transfected with the indicated expression plasmids for 20 h. HeLa cells were treated with dsDNA and Sorafenib for the indicated times. Cells then were lysed in lysis buffer (1% Triton X-100, 150 mM NaCl, 12.5 mM β-glycerolphosphate, 1.5 mM MgCl2, 2 mM EGTA, 10 mM NaF, 1 mM Na3VO4, 2 mM DTT) containing protease inhibitors. Lysates were centrifuged and the supernatants were incubated with anti-Flag beads or with Protein A/G Sepharose (Amersham) plus anti-IRF3, anti-p-IRF3, antiviperin and anti-GFP antibodies for at least 4 h. The beads were washed with cold PBS for three times and eluted with DTT-containing SDS sample buffer by boiling for 10 min before Western blot analysis.

The literature inference in this work was supported by an AI platform named 'Drug Discovery Brain' of Infinity Intelligent Pharma Co., Ltd. We thank Dr. Youjun Xu and Dr. Weilin Zhang for their help in computer programming and data processing.

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Emerging coronaviruses: Genome structure, replication, and pathogenesis

STING: infection, inflammation and cancer

ERIS, an endoplasmic reticulum IFN stimulator, activates innate immune signaling through dimerization

DNA sensing by the cGAS-STING pathway in health and disease

Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations

Type I IFN expression is stimulated by cytosolic MtDNA released from pneumolysindamaged mitochondria via the STING signaling pathway in macrophages

ALK is a therapeutic target for lethal sepsis

Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing

Drug developers switch gears to inhibit STING

cGAS in action: Expanding roles in immunity and inflammation

Targeting Stimulator of Interferon Genes (STING): A Medicinal Chemistry Perspective

The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration

Suramin potently inhibits cGAMP synthase, cGAS, in THP1 cells to modulate IFN-beta levels

Suramin Inhibits Chikungunya Virus Entry and Transmission

Polysulfonate suramin inhibits Zika virus infection

Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry

Discovery of highly potent microsomal prostaglandin e2 synthase 1 inhibitors using the active conformation structural model and virtual screen

DOCK 6: combining techniques to model RNA-small molecule complexes

CD14 is required for MyD88-independent LPS signaling